Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

ConclusionsBI 853520 has a manageable and acceptable safety profile, favorable PK, and modest antitumor activity at an MTD of 200  mg QD in patients with selected advanced nonhematologic malignancies.ClinicalTrials.gov identifierNCT01335269.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research